reta10 Next-Gen Dual Chamber Pen

Reta-Tik™ GLP3 Next-Gen Dual-Chamber Pen

Pen (Ready-to-use) / 10mg
Fast Delivery
990.00 AED 1,490.00 AED
Skip to product information
-34% OFF
reta10 Next-Gen Dual Chamber Pen
  • reta10 Next-Gen Dual Chamber Pen
Content 1 pen 10 mg Reta-Tik
Content 1 vial 10 mg Reta-Tik
1 vial 3 mL Bacteriostatic Water included
Content 1 pen 10 mg Reta-Tik
Duration cycle 6 months or 1 year
Duration cycle 6 months or 1 year
Duration cycle 6 months or 1 year
Reconstitution Twist and Mix (Fresh mix)
Reconstitution Use only 1 mL for reconstitution
Dosage 20 units / injection 40 units / injection 60 units / injection2 mg / injection 4 mg / injection 6 mg / injection
Pens required 1 pen / month at 2 mg 2 pens / month at 4 mg 3 pens / month at 6 mg
Vials required 1 vial / month at 2 mg
2 vials / month at 4 mg
3 vials / month at 6 mg
Bottles required
Dosage 20 units2 mg 40 units4 mg 60 units6 mgper injection
Dosage 20 units0.2 ml · 2 mg 40 units0.4 ml · 4 mg 60 units0.6 ml · 6 mgper injection
Frequency Once weekly, morningAlways the same day
Frequency Once weekly, morningAlways the same day
Frequency MorningOne injection per week

Dosage examples are for research-reference only. Not medical advice and not personal recommendation

RUO Best Seller Pen WEIGHT LOSS

Reta-Tik™ GLP3 Next-Gen Dual-Chamber Pen

Fast Weight loss · Visceral fat · Appetite control · GLP1 · GIP · Glucagon

Co-developed with 600+ researchers

  • French Lab Tested 🇫🇷
  • 99%+ Purity Target
  • HPLC & HRMMS Verified
  • 90,000+ packages delivered worldwide
  • QR Batch Reports
  • Secure Checkout
  • Fast International Shipping (3-5 days)
  • 90,000+ packages delivered worldwide

About Reta-Tik™

Triple-Receptor Action · GLP-1 · GIP · Glucagon · Appetite Signaling · Energy Metabolism

BEYOND A SINGLE TARGET. THREE METABOLIC PATHWAYS.

The triple-receptor concept behind Reta-Tik™ brings together GLP-1, GIP and glucagon receptor activation in a single investigational molecule. These pathways are involved in appetite regulation, glucose control and energy metabolism, creating a distinct approach to metabolic science.

Beyond Dual-Receptor Signaling

Tirzepatide activates GLP-1 and GIP receptors. The triple-receptor approach adds glucagon receptor activation.

That third target is the defining difference. In preclinical studies, glucagon receptor activation contributed to increased energy expenditure, alongside reduced food intake associated with incretin receptor activation. A broader mechanism does not, by itself, prove better clinical results.

Clinical Data That Commands Attention

A 2023 phase 2 trial published in The New England Journal of Medicine, involving 338 adults with obesity or overweight and a weight-related condition, reported mean body-weight reductions in the 12 mg study group of:

17.5% at 24 weeks

24.2% at 48 weeks

The corresponding placebo reductions were 1.6% and 2.1%. These percentages are study-group averages under controlled conditions, not guaranteed individual outcomes.

For context, the separate SURMOUNT-1 trial reported 22.5% mean body-weight reduction at 72 weeks in the tirzepatide 15 mg group, using an analysis estimating outcomes with continued treatment.

More Than Appetite Alone

Appetite is one part of the metabolic picture.

The triple-receptor approach examines how food intake, glucose regulation and energy expenditure interact. Its distinguishing feature is the combination of incretin signaling with glucagon receptor activity, rather than a focus on a single biological target.

Reta-Tik™. Triple-receptor science. A distinct metabolic approach.



Select Variant
Dosage
Quantity
1 Box

Certificate of Analysis available for every batch.

Secure checkout • Fast UAE dispatch • Research Use Only

Request Certificate of Analysis COA

Secure checkout

Fast UAE dispatch

Request Certificate of Analysis COA
Questions about this peptide? Chat directly with our research specialists Ask on WhatsApp

Why Peptik Next-Gen Dual-Chamber Technology Changes Everything ?

Dual-Chamber Advantage

Features Traditional Single-Chamber Systems Peptik Advanced Dual-Chamber Technology
Peptide Effectiveness During Use ★★★★★ ★★★★★
Mixing Process Pre-mixed by the manufacturer weeks or months before delivery Freshly mixed only at the moment of preparation
Compound Quality at Delivery Stability and peptide efficiency reduced at the time of delivery Designed to help preserve optimal compound stability until preparation
Shelf Life at Room Temperature Few hours of ambient stability, with increased degradation risk during shipment and supply chain handling Up to 4 weeks
Shelf Life at 2–8°C (Fridge) Up to 4 weeks after mixing. If the pen was manufactured one month before first use, peptide stability is compromised Up to 24 months before preparation by keeping peptide and diluent separated
Storage Flexibility Requires continuous cold-chain management after mixing Dry isolated compounds allow improved storage flexibility before preparation
Production Cost Low cost Higher production cost due to advanced dual-chamber technology
Manufacturer Priority Cost reduction and simplified production Stability preservation and premium compound protection
Reta-Tik™ GLP3 Next-Gen Dual-Chamber Pen

About the Product

About Reta-Tik™

Triple-Receptor Action · GLP-1 · GIP · Glucagon · Appetite Signaling · Energy Metabolism

BEYOND A SINGLE TARGET. THREE METABOLIC PATHWAYS.

The triple-receptor concept behind Reta-Tik™ brings together GLP-1, GIP and glucagon receptor activation in a single investigational molecule. These pathways are involved in appetite regulation, glucose control and energy metabolism, creating a distinct approach to metabolic science.

Beyond Dual-Receptor Signaling

Tirzepatide activates GLP-1 and GIP receptors. The triple-receptor approach adds glucagon receptor activation.

That third target is the defining difference. In preclinical studies, glucagon receptor activation contributed to increased energy expenditure, alongside reduced food intake associated with incretin receptor activation. A broader mechanism does not, by itself, prove better clinical results.

Clinical Data That Commands Attention

A 2023 phase 2 trial published in The New England Journal of Medicine, involving 338 adults with obesity or overweight and a weight-related condition, reported mean body-weight reductions in the 12 mg study group of:

17.5% at 24 weeks

24.2% at 48 weeks

The corresponding placebo reductions were 1.6% and 2.1%. These percentages are study-group averages under controlled conditions, not guaranteed individual outcomes.

For context, the separate SURMOUNT-1 trial reported 22.5% mean body-weight reduction at 72 weeks in the tirzepatide 15 mg group, using an analysis estimating outcomes with continued treatment.

More Than Appetite Alone

Appetite is one part of the metabolic picture.

The triple-receptor approach examines how food intake, glucose regulation and energy expenditure interact. Its distinguishing feature is the combination of incretin signaling with glucagon receptor activity, rather than a focus on a single biological target.

Reta-Tik™. Triple-receptor science. A distinct metabolic approach.



RETA-Tik 20 mg Pen instructions, front RETA-Tik 20 mg Pen instructions, back

Storage Guidelines

To maintain product integrity, proper storage conditions are recommended throughout handling and use.

Unreconstituted (lyophilized) peptide

  • Store at 2–8°C (in the fridge) for short-term use
  • For extended storage, keep at -20°C or below (in the freezer)
  • Protect from direct light and moisture

Reconstituted solution

  • Store at 2–8°C and use within a limited timeframe
  • For longer-term storage, aliquoting and freezing at -20°C is recommended
  • Avoid repeated freeze-thaw cycles, as this may affect peptide stability

Worldwide delivery in 3–5 days.

Peptik orders are prepared with secure handling and fast logistics for international customers.

  • International shipping within 3–5 days
  • Secure checkout and protected payment
  • Carefully handled dispatch
  • Batch documentation available for every order

Recommended for you

Customers who purchased Reta-Tik™ GLP3 Next-Gen Dual-Chamber Pen also ordered

View full catalogue
Ending Soon

Exclusive Offer

A curated selection of our most complete protocols, offered at a limited preferential rate.

Verified reviews

What researchers say

4.9 / 5 from 130 verified reviews

Frequently Asked Questions

Answers to common questions about PEPTIK products, regulatory positioning, and laboratory use.

View full FAQ

Yes. Each production batch undergoes High Performance Liquid Chromatography (HPLC) purity testing, mass spectrometry peptide identity verification and full batch traceability documentation. A Certificate of Analysis is available for every lot.

Store at 2–8°C in the fridge for short-term use, or at -20°C or below in the freezer for extended storage. Avoid repeated freeze-thaw cycles. For pre-filled pens, use within 5 weeks after mixing.

No. The peptide is supplied in a pre-filled dual-chamber pen as a ready-to-use solution, eliminating the need for reconstitution or additional preparation steps. Protect from contamination during use.

Ships from our UAE warehouse. International delivery typically takes 3–5 business days. Delivery timing and customs requirements vary by destination.

Yes. A Certificate of Analysis (COA) is available for every batch, documenting HPLC purity testing, mass spectrometry identity verification and full batch traceability. Available upon request to qualified research entities.

Every production batch undergoes High Performance Liquid Chromatography (HPLC) purity testing, mass spectrometry peptide identity verification, and is logged with full batch traceability documentation. Quality control is performed in France.

View full FAQ